Outgrowth of BT-474 human breast cancer cells in immune-deficient mice: a new in vivo model for hormone-dependent breast cancer.
The effect of co-inoculation of basement membrane matrix, Matrigel and two human breast cancer cell lines, BT-474 and SK-BR-3, was tested in immune-deficient mice. Both cell lines strongly overexpress c-ErbB-2 protein, whereas only BT-474 is reported to be oestrogen receptor positive. Co-inoculation of Matrigel and BT-474 cells but not of Matrigel and SK-BR-3 cells resulted in tumour formation in bg-nu-xid mice. Oestrogen supplementation greatly enhanced tumorigenicity, but did not seem to be an absolute requirement. In vivo, BT-474 cells grow as a poorly differentiated adenocarcinoma with a doubling time of 9.4 +/- 1.1 days after inoculation into the neck region. A high proliferative activity appears to be compensated by a relatively high rate of cell loss, as BT-474 tumours contain many cells with the typical morphology of apoptotic cell death. Wild-type p53, known to participate in the induction of apoptosis, is absent from the tumours, whereas Bcl-2, known to inhibit apoptosis, is expressed at intermediate levels. BT-474 tumours tend to metastasise to the regional lymph nodes and are capable of forming micrometastatic lesions in the lung. Flow cytometrical analysis of DNA ploidy demonstrated no change in tumours compared with the cell line. Immunohistochemical and flow cytometrical detection of a number of hormone and growth factor receptors, transcription factors, cell adhesion molecules and proteins involved in proliferation and cell death demonstrated no major changes in ploidy and phenotype of tumours compared with the cell line. High expression of the cell-surface molecules c-ErbB-2 and episialin make it a potentially useful model for research in immune therapy.
van Slooten
H J
HJ
Department of Surgery, Leiden University Hospital, The Netherlands.
Bonsing
B A
BA
Hiller
A J
AJ
Colbern
G T
GT
van Dierendonck
J H
JH
Cornelisse
C J
CJ
Smith
H S
HS
D000818:Animals; D001943:Breast Neoplasms / Q000737:chemistry / Q000473:pathology*; D002453:Cell Cycle; D003094:Collagen / Q000494:pharmacology; D004195:Disease Models, Animal; D004338:Drug Combinations; D005260:Female; D006801:Humans; D007153:Immunologic Deficiency Syndromes / Q000235:genetics; D007797:Laminin / Q000494:pharmacology; D051379:Mice; D009368:Neoplasm Transplantation; D009376:Neoplasms, Hormone-Dependent / Q000473:pathology*; D011509:Proteoglycans / Q000494:pharmacology; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000032:analysis; D011960:Receptors, Estrogen / Q000032:analysis*; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured
D003094:Collagen; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C059485:matrigel